Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 3Genitourinary 2Gynecologic 1

Conditions

Urinary Bladder Neoplasms 2

Interventions

Docetaxel 77Radiotherapy 73Prednisone 65Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 41Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 30Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Triptorelin Pamoate 23Sunitinib 23Nivolumab 23Radiation 22apalutamide 21Doxorubicin 20darolutamide 18Gonadotropin-Releasing Hormone 18cabozantinib 16abiraterone 16Specimen Handling 16Radiosurgery 16Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × alvimopan × Genitourinary × Clear all
NCT06703476 2026-01-27

A Study of Surgical Techniques During Cystectomy

Memorial Sloan Kettering Cancer Center

Phase 3 Recruiting
530 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03216525 2023-09-28

Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Brigham and Women's Hospital

Phase 3 Recruiting
136 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡